Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-dose Colchicine for CABG Graft Failure Prevention
Sponsor: Beijing Anzhen Hospital
Summary
This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Official title: Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
622
Start Date
2026-09-01
Completion Date
2029-09-01
Last Updated
2026-05-06
Healthy Volunteers
No
Interventions
Colchicine Pill
Colchicine 0.5 mg once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.
Placebo
Placebo one tablet once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.
Locations (1)
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China